What is the difference between Aimovig and Emgality?

Same class. Both Aimovig and Emgality are CGRP inhibitors, so they work through the same broad mechanism. Differences between them tend to be about dosing, route, how selective they are, and side effects rather than what they target.

Are Aimovig and Emgality the same drug?

No. Aimovig is the brand name for Erenumab and Emgality is the brand name for Galcanezumab. They are different active ingredients.

Is Aimovig a tablet or an injection?

Aimovig is given by the subcutaneous route; Emgality by the subcutaneous route.

Who makes Aimovig and Emgality?

Aimovig is marketed by Amgen; Emgality by Eli Lilly. (FDA application holder, per Drugs@FDA.)

← All drug comparisons

Aimovig vs Emgality

Erenumab · Galcanezumab

Both are CGRP inhibitors. Here is how Aimovig and Emgality compare on class, mechanism, dosing, approval and supply.

Reviewed by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from official FDA data · Last verified 8 Oct 2026 · Editorial standards

At a glance

AimovigErenumab

EmgalityGalcanezumab

Brand name

Aimovig

Emgality

Drug class

CGRP receptor antagonist

CGRP inhibitor

Route

Subcutaneous

Marketed by

Amgen

Eli Lilly

First FDA approval

17 May 2018

27 Sep 2018

US shortage

Not listed

Key differences

Same class. Both Aimovig and Emgality are CGRP inhibitors, so they work through the same broad mechanism. Differences between them tend to be about dosing, route, how selective they are, and side effects rather than what they target.
How they are taken. Both are given by the subcutaneous route.
Time on the market. Aimovig was first approved by the FDA in 2018, Emgality in 2018.
Who markets them. Aimovig is marketed by Amgen; Emgality by Eli Lilly.

What each one treats

AimovigErenumab

AIMOVIG is indicated for the preventive treatment of migraine in adults. AIMOVIG is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. ( 1 )

EmgalityGalcanezumab

EMGALITY ® is a calcitonin-gene related peptide antagonist indicated in adults for the: preventive treatment of migraine. ( 1.1 ) treatment of episodic cluster headache. ( 1.2 ) 1.1 Migraine EMGALITY is indicated for the preventive treatment of migraine in adults. 1.2 Episodic Cluster Headache EMGALITY is indicated for the treatment of episodic cluster headache in adults.

How each one works

AimovigCGRP receptor antagonist

12.1 Mechanism of Action Erenumab-aooe is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function.

EmgalityCGRP inhibitor

12.1 Mechanism of Action Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.

Related comparisons

Aimovig VS Ajovy Aimovig VS Nurtec ODT Aimovig VS Ubrelvy Emgality VS Ajovy Emgality VS Nurtec ODT Emgality VS Ubrelvy

Aimovig profile Emgality profile CGRP Inhibitors All comparisons

This is not a recommendation of one drug over the other.

Which medicine is right for a given person depends on their diagnosis, other conditions, other medicines, kidney and liver function, pregnancy, and cost or reimbursement — none of which this page knows. Two drugs in the same class are not automatically interchangeable. Never start, stop or switch a prescription medicine on the basis of a web page; that decision belongs to you and your clinician or pharmacist.

How this page is built

The facts on this page are pulled directly from official U.S. FDA datasets — they are not written from memory. Each field below names the dataset it came from, so you can check it yourself.

FDA Drug Label (openFDA) ↗ Indications, mechanism of action and pharmacologic class
Drugs@FDA ↗ First FDA approval date and the company holding the application
FDA Drug Shortage Database ↗ Current US supply / shortage status

Plain-English summaries and drug-class explainers are written and reviewed by Sreepriya Prasannan (MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany). Data is retrieved automatically from the sources above and cross-checked with AI-assisted verification (Anthropic's Claude) — brand and generic names are matched against the exact FDA product record so that a combination product or a different formulation cannot be mistaken for the drug on this page. An editor reviews the result before publication. We describe this in full in our editorial standards and corrections policy. The FDA data on this page was last retrieved on 8 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.